SCHEMBL13618663

SCHEMBL13618663

CC(C)C(=O)C(N)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4761841 1.00 — —
SCHEMBL21345128 1.00 — —
SCHEMBL13213464 0.82 — —
SCHEMBL31267174 0.81 GABRP (0.42) —
SCHEMBL14660183 0.81 — —
SCHEMBL23897859 0.81 GABRP (0.42) —
SCHEMBL12937988 0.81 GABRP (0.42) —
SCHEMBL24994838 0.79 — —
SCHEMBL7555148 0.78 — —
SCHEMBL2625543 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES MIHKAL GMBH (CH) 2023-10-12 — — US disclosed
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES MIHKAL GMBH (CH) 2023-10-12 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20210220477-A1 SITE SPECIFIC ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS MERSANA THERAPEUTICS, INC. 2021-07-22 — — US disclosed
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-06-03 — — US disclosed
US-20200276211-A1 COMPOUNDS FOR TREATING NEAR VISION DISORDERS VIEWPOINT THERAPEUTICS INC (US) 2020-09-03 — — US disclosed
WO-2019245890-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2019-12-26 — — WO disclosed
WO-2019134530-A1 NOVEL ANTIBIOTICS AND METHODS OF USING THEM VERSITECH LIMITED (CN) 2019-07-11 — — WO disclosed
US-9884865-B2 Azaspiro[4.5] decane derivatives and use thereof PURDUE PHARMA L.P. (US) 2018-02-06 — — US disclosed
US-8791134-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2014-07-29 — — US disclosed
US-20140120141-A1 PEPTIDES USEFUL IN THE TREATMENT AND CARE OF THE SKIN AND MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS LIPOTEC S.A. (ES) 2014-05-01 — — US disclosed
US-20140120141-A1 PEPTIDES USEFUL IN THE TREATMENT AND CARE OF THE SKIN AND MUCOUS MEMBRANES AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS LIPOTEC S.A. (ES) 2014-05-01 — — US disclosed
US-8709431-B2 Enediyne compounds, conjugates thereof, and uses and methods therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-29 — — US disclosed
US-20130209494-A1 ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-15 — — US disclosed
US-20130045951-A1 Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2013-02-21 — — US disclosed
US-8318705-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2012-11-27 — — US disclosed
US-8318705-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2012-11-27 — — US disclosed
US-20090281062-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF EVOTEC LTD. (GB) 2009-11-12 — — US disclosed
US-20090281062-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF EVOTEC LTD. (GB) 2009-11-12 — — US disclosed
Send feedback